Astellas Pharma Stock Net Income
| YPH Stock | EUR 9.50 0.20 2.15% |
Astellas Pharma fundamentals help investors to digest information that contributes to Astellas Pharma's financial success or failures. It also enables traders to predict the movement of Astellas Stock. The fundamental analysis module provides a way to measure Astellas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Astellas Pharma stock.
Astellas |
Astellas Pharma Company Net Income Analysis
Astellas Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Astellas Pharma Net Income | 124.09 B |
Most of Astellas Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Astellas Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Astellas Pharma reported net income of 124.09 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net income for all Germany stocks is significantly lower than that of the firm.
Astellas Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Astellas Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Astellas Pharma could also be used in its relative valuation, which is a method of valuing Astellas Pharma by comparing valuation metrics of similar companies.Astellas Pharma is currently under evaluation in net income category among its peers.
Astellas Fundamentals
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 24.85 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 50.33 % | |||
| Price To Earning | 29.54 X | |||
| Price To Book | 2.44 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 1.3 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 241.52 B | |||
| Net Income | 124.09 B | |||
| Cash And Equivalents | 305.99 B | |||
| Cash Per Share | 165.15 X | |||
| Total Debt | 308 M | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 847.56 X | |||
| Cash Flow From Operations | 257.44 B | |||
| Earnings Per Share | 0.52 X | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 23.71 B | |||
| Total Asset | 2.33 T | |||
| Z Score | 45.6 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 2.35 % | |||
| Net Asset | 2.33 T | |||
| Last Dividend Paid | 55.0 |
About Astellas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Astellas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astellas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astellas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Astellas Stock
Astellas Pharma financial ratios help investors to determine whether Astellas Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.